Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
{{output}}
Background: There are limited clinical data to compare the efficacy of trastuzumab deruxtecan (T-DXd) between the immunohistochemistry (IHC) 1+ and 2+ subgroups of human epidermal growth factor receptor 2 (HER2)-low metastatic br... ...
